As your constituent, I am writing to urge you to support S. 1064, the National Plan to End Parkinson’s Act. This landmark bill is the first of its kind to address Parkinson’s disease on a large scale. Equally crucial, it also covers Lewy Body dementia (LBD) and the “atypical Parkinsonian” diseases: progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA).
As you know, on December 14, 2023, the companion bill, H.R. 2365 (the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinson's Act), passed the House of Representatives by a vote of 407 to 9.&nbsp;&nbsp;&nbsp;
S. 1064, sponsored by Senator Shelly Moore Capito and Senator Chris Murphy, is bipartisan and no-cost legislation that would create an advisory council to coordinate federal efforts to: prevent and cure Parkinson’s and the atypical Parkinsonian diseases, alleviate financial and health burdens on American families, ensure those living with the diseases have access to the care they need, and report annually to Congress on the progress made to end the diseases. As a constituent that is personally impacted by an atypical Parkinsonian diagnosis, the passage of this legislation is of utmost importance to me.
It is critical to highlight the inclusion of the atypical Parkinsonian diseases in this bill. Unlike Parkinson’s disease, the road to a correct clinical diagnosis is long due to unfamiliarity among healthcare professionals, they progress quickly and medications have limited efficacy. They have complex and high care needs, yet because they are rare, they have substantially less research and awareness within the medical community. To learn more about PSP, CBD and MSA, please visit www.curepsp.org
S. 1064 takes a bold and holistic approach to improving quality of care and life for people with Parkinson’s, LBD, PSP, CBD, and MSA and working towards a world without these diseases. By supporting this bill, you are offering hope to the many thousands of patients, families, medical professionals, and researchers across the country.
To co-sponsor or learn more about the National Plan to End Parkinson’s Act (S. 1064), please contact: Dana Richter (dana_richter@capito.senate.gov, 202-224-6472) in the office of Senator Shelly Moore Capito or Marisa Salemme (marisa_salemme@murphy.senate.gov, 202-224-4041) in the office of Senator Chris Murphy.
I look forward to your response and thank you for your support of the Parkinsonian community!&nbsp;&nbsp;&nbsp;&nbsp;

The below message will be sent to the elected policymakers for your district and state. While not required, please feel free to add a brief (recommended: no more than a few sentences) personal message to accompany it. Thank you for advocating with CurePSP!

As your constituent, I am writing to urge you to support S. 1064, the National Plan to End Parkinson’s Act. This landmark bill is the first of its kind to address Parkinson’s disease on a large scale. Equally crucial, it also covers Lewy Body dementia (LBD) and the “atypical Parkinsonian” diseases: progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA). 

As you know, on December 14, 2023, the companion bill, H.R. 2365 (the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinson's Act), passed the House of Representatives by a vote of 407 to 9. 

S. 1064, sponsored by Senator Shelly Moore Capito and Senator Chris Murphy, is bipartisan and no-cost legislation that would create an advisory council to coordinate federal efforts to: prevent and cure Parkinson’s and the atypical Parkinsonian diseases, alleviate financial and health burdens on American families, ensure those living with the diseases have access to the care they need, and report annually to Congress on the progress made to end the diseases. As a constituent that is personally impacted by an atypical Parkinsonian diagnosis, the passage of this legislation is of utmost importance to me.  

It is critical to highlight the inclusion of the atypical Parkinsonian diseases in this bill. Unlike Parkinson’s disease, the road to a correct clinical diagnosis is long due to unfamiliarity among healthcare professionals, they progress quickly and medications have limited efficacy. They have complex and high care needs, yet because they are rare, they have substantially less research and awareness within the medical community. To learn more about PSP, CBD and MSA, please visit www.curepsp.org  

S. 1064 takes a bold and holistic approach to improving quality of care and life for people with Parkinson’s, LBD, PSP, CBD, and MSA and working towards a world without these diseases. By supporting this bill, you are offering hope to the many thousands of patients, families, medical professionals, and researchers across the country.  

To co-sponsor or learn more about the National Plan to End Parkinson’s Act (S. 1064), please contact:  

Dana Richter (dana_richter@capito.senate.gov, 202-224-6472) in the office of Senator Shelly Moore Capito or Marisa Salemme (marisa_salemme@murphy.senate.gov, 202-224-4041) in the office of Senator Chris Murphy. 

I look forward to your response and thank you for your support of the Parkinsonian community!

Dear Office Holder (names will be automatically added on each email),